Sign In
Buy GLPG
$27.38
+0.0650 (+0.238%)
At Close: Jun 03, 2026
Potential Gilead Blockbusters Were Rejected By the FDA. Why That’s the ‘Near-Worst-Case Scenario’ for the Stock.
02:42pm, Wednesday, 19'th Aug 2020
The Food and Drug Administration rejected Gilead Sciences’ application for a would-be blockbuster arthritis drug Tuesday night, blindsiding investors.
Gilead arthritis drug won't be approved by FDA in current form, partner Galapagos says
07:46am, Wednesday, 19'th Aug 2020
Gilead Sciences investigational treatment for moderately to severely active rheumatoid arthritis won't be approved by the U.S. Food and Drug Administration in current form, its partner Galapagos sai
Gilead Sinks After-Hours As FDA Rejects Rheumatoid Arthritis Application
06:48am, Wednesday, 19'th Aug 2020
Gilead Sciences (GILD) has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for filgotinib, an investigational treatment fo
Gilead's Rheumatoid Arthritis Drug Application Is A No-Go In Present Form: FDA
04:29am, Wednesday, 19'th Aug 2020
Gilead Sciences, Inc (NASDAQ: GILD) shares took a jolt in the after-hours session Tuesday as it announced its application for filgotinib, an investigational treatment for moderately to severely active
* * * Mechelen, Belgium; 19 August 2020, 01.25 CET; regulated information – Galapagos (Euronext & Nasdaq: GLPG) announces today that Gilead Sciences, Inc. (Nasdaq: GILD) received a complete respons
Stocks To Watch: Walmart, Target, Kandi And Gold vs. Bitcoin
08:30am, Saturday, 15'th Aug 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
Scipher Medicine and Galapagos sign collaboration in inflammatory bowel disease
08:01pm, Wednesday, 12'th Aug 2020
\-- Companies to jointly validate novel drug targets -- \-- Scipher eligible for upfront, opt-in and milestone payments -- \-- Galapagos to progress selected targets into drug discovery -- Mechelen,
Galapagos reports solid H1 2020 progress
08:01pm, Thursday, 06'th Aug 2020
* First half-year 2020 financial results: * Group revenues and other income of €224.6 million * Operating loss of €130.8 million * Net loss of €165.6 million * Cash and current finan
Gilead: Perhaps A Value Trap No Longer
11:20am, Sunday, 02'nd Aug 2020
GILD sank back into its familiar pattern of disappointing the Street, selling off below $70 again after reporting Q2 results.
\-- Clinical Development Program of Filgotinib Demonstrated Durable Efficacy Balanced with a Consistent Safety Profile in Rheumatoid Arthritis Through 52 Weeks -- Foster City, Calif., and Mechelen, B
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) announced today the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted
5 Greenblatt Magic Formula Biotech Stocks to Weather the Summer Coronavirus Storm
10:48pm, Tuesday, 07'th Jul 2020
Stocks to consider as biotech company Novavax gets $1.6 billion in federal aid for Covie-19 vaccine Continue reading...
Better Buy: Vertex Pharmaceuticals vs. Galapagos
02:38pm, Thursday, 02'nd Jul 2020
Is an industry leader in treating cystic fibrosis or a company with a potential miracle drug the better buy for investors?
Hedge Funds Are Warming Up To Galapagos NV (GLPG)
04:31pm, Friday, 26'th Jun 2020
In this article we will take a look at whether hedge funds think Galapagos NV (NASDAQ:GLPG) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into h
AstraZeneca Ponders a Huge $240 Billion Gilead Gamble
03:15pm, Sunday, 07'th Jun 2020
(Bloomberg Opinion) -- There are good reasons for Britain’s AstraZeneca Plc to consider what would be the biggest pharmaceuticals deal in history by combining with U.S. peer Gilead Sciences Inc. Th
